Open AccessEffect of Nebivolol on MPTP Induced Parkinson’s Disease in Mice
Author(s) -
K Karthigadevi.,
S. Anbazhagan,
Jajjara Gopi Sudheer Kumar,
S Kavimani
Publication year - 2021
Publication title -
international journal of pharmaceutical sciences review and research
Language(s) - English
Resource type - Journals
ISSN - 0976-044X
DOI - 10.47583/ijpsrr.2021.v69i01.020
Subject(s) - mptp , nebivolol , parkinson's disease , dopaminergic , oxidative stress , dopamine , medicine , pharmacology , inflammation , resting tremor , substantia nigra , disease , neuroscience , psychology , blood pressure
Parkinson’s disease is the major neurodegenerative disorder, which is due to the loss of dopaminergic neurons in the brain and resultsin bradykinesia, rigidity, tremor and instable posture. Oxidative stress, Inflammation, Apoptosis has been implicated in the molecular etiopathogenesis of Parkinson disease. In the present study, Nebivolol, a Cardioselective ?-blocking agent which is also reported as an antioxidant, anti-inflammation, anticonvulsant, inhibition of apoptosis and protective effects on gastric ulcer. Hence, nebivolol has been tested for its antiparkinson activity against 1-Methyl, 4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) induced model of Parkinson disease in mice. From this study, the result shown that the nebivolol exerts its beneficial effect against MPTP induced Parkinson’s disease by virtue of its antioxidative, anti-inflammatory and by increases the Dopamine levels in the brain.